Noninvasive Test Approved for the Evaluation of Coronary Artery Disease
By MedImaging International staff writers Posted on 14 Jan 2015 |
Image: 3-D Representation of the Heart and Coronary Arteries (Photo courtesy of HeartFlow).
The US Food and Drug Administration (FDA) have allowed marketing of the HeartFlow (Redwood City, CA, USA) FFR-CT software.
Normally Fractional Flow Reserve (FFR) data is obtained from an invasive cardiac catheterization procedure. The HeartFlow application uses data from a standard Computed Tomography (CT) scan and enables healthcare professionals to measure ischemia, and create a 3-D model of the blood flow in the coronary arteries of a patient with symptoms of coronary heart disease. HeartFlow provides noninvasive evaluation of blockages in coronary arteries using computational fluid dynamics and can help evaluate the effectiveness of placing a stent, angioplasty, or surgery.
In tests HeartFlow FFR-CT was found to be 84%-86% accurate in differentiating significant coronary artery blockages that need revascularization from those that do not, and provides a fast, noninvasive method for the diagnosis of coronary heart disease.
William Maisel, MD, MPH, deputy director for science and chief scientist in the FDA’s Center for Devices and Radiological Health stated, “This noninvasive method is an additional tool for clinicians who are considering the risks and benefits of invasive coronary procedures.”
Related Links:
HeartFlow
Normally Fractional Flow Reserve (FFR) data is obtained from an invasive cardiac catheterization procedure. The HeartFlow application uses data from a standard Computed Tomography (CT) scan and enables healthcare professionals to measure ischemia, and create a 3-D model of the blood flow in the coronary arteries of a patient with symptoms of coronary heart disease. HeartFlow provides noninvasive evaluation of blockages in coronary arteries using computational fluid dynamics and can help evaluate the effectiveness of placing a stent, angioplasty, or surgery.
In tests HeartFlow FFR-CT was found to be 84%-86% accurate in differentiating significant coronary artery blockages that need revascularization from those that do not, and provides a fast, noninvasive method for the diagnosis of coronary heart disease.
William Maisel, MD, MPH, deputy director for science and chief scientist in the FDA’s Center for Devices and Radiological Health stated, “This noninvasive method is an additional tool for clinicians who are considering the risks and benefits of invasive coronary procedures.”
Related Links:
HeartFlow
Latest Radiography News
- Novel Breast Imaging System Proves As Effective As Mammography
- AI Assistance Improves Breast-Cancer Screening by Reducing False Positives
- AI Could Boost Clinical Adoption of Chest DDR
- 3D Mammography Almost Halves Breast Cancer Incidence between Two Screening Tests
- AI Model Predicts 5-Year Breast Cancer Risk from Mammograms
- Deep Learning Framework Detects Fractures in X-Ray Images With 99% Accuracy
- Direct AI-Based Medical X-Ray Imaging System a Paradigm-Shift from Conventional DR and CT
- Chest X-Ray AI Solution Automatically Identifies, Categorizes and Highlights Suspicious Areas
- AI Diagnoses Wrist Fractures As Well As Radiologists
- Annual Mammography Beginning At 40 Cuts Breast Cancer Mortality By 42%
- 3D Human GPS Powered By Light Paves Way for Radiation-Free Minimally-Invasive Surgery
- Novel AI Technology to Revolutionize Cancer Detection in Dense Breasts
- AI Solution Provides Radiologists with 'Second Pair' Of Eyes to Detect Breast Cancers
- AI Helps General Radiologists Achieve Specialist-Level Performance in Interpreting Mammograms
- Novel Imaging Technique Could Transform Breast Cancer Detection
- Computer Program Combines AI and Heat-Imaging Technology for Early Breast Cancer Detection